Director's Share Purchase
2007年12月6日 - 6:30PM
RNSを含む英国規制内ニュース (英語)
RNS Number:3151J
Arana Therapeutics Limited
06 December 2007
For Immediate Release 6 December 2007
ARANA THERAPEUTICS LTD
DIRECTOR'S SHARE PURCHASE
Arana Therapeutics Ltd, (LSE: AAHx ASX: AAH) ("Arana" or the "Company"), the
Australian biopharmaceutical company, formed through the merger of Peptech and
EvoGenix in August 2007. The Company uses superior technology to develop next
generation drugs that will improve the lives of patients with inflammatory
diseases and cancer. The Company has received notification on 3 December 2007
that the following Director purchased ordinary fully paid shares in the capital
of the Company. Details are as follows:
Director Direct or No. of Date Price per Total Subsequent
Indirect Ordinary Purchased Share (A$) Consideration beneficial
Interest Shares (A$) holding
purchased
Robin Beaumont Indirect 13,352 3 December 2007 1.147 15,312 139,000
For further information, please contact:
Arana Therapeutics Ltd
Dr John Chiplin, Chief Executive Officer +61 (0)2 9870 8788
Niall Henderson, Chief Financial Officer +61 (0)2 9870 8788
Buchanan Communications
Lisa Baderoon (lisab@buchanan.uk.com) +44 (0)20 7466 5000
Rebecca Skye Dietrich / Catherine Breen
Nomura Code Securities
Charles Walker +44 (0)20 7776 1206
This information is provided by RNS
The company news service from the London Stock Exchange
END
RDSFSWSUMSWSEEE
Arana Therap. (LSE:AAHX)
過去 株価チャート
から 5 2024 まで 6 2024
Arana Therap. (LSE:AAHX)
過去 株価チャート
から 6 2023 まで 6 2024
Real-Time news about Arana Therap. (ロンドン証券取引所): 0 recent articles
その他のArana Therapeuticsニュース記事